国药股份
(600511)
| 流通市值：199.92亿 | | | 总市值：272.60亿 |
| 流通股本：5.53亿 | | | 总股本：7.55亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 38,028,539,709.49 | 24,756,503,031.47 | 12,122,142,562.33 | 49,696,045,528.87 |
| 营业收入 | 38,028,539,709.49 | 24,756,503,031.47 | 12,122,142,562.33 | 49,696,045,528.87 |
| 二、营业总成本 | 36,311,068,962.03 | 23,626,002,706.25 | 11,584,004,995.37 | 47,194,088,893.72 |
| 营业成本 | 35,359,757,294.67 | 23,003,398,921.29 | 11,270,055,777.5 | 45,704,776,081.97 |
| 税金及附加 | 88,941,449.62 | 57,348,752.67 | 26,821,986.63 | 114,735,965.78 |
| 销售费用 | 582,151,421.92 | 388,692,076.23 | 201,454,461.53 | 962,378,292.42 |
| 管理费用 | 309,744,686.29 | 200,453,847.88 | 100,533,956.36 | 467,127,883.37 |
| 研发费用 | 44,141,243.81 | 28,795,929.7 | 13,941,626.51 | 71,197,375.91 |
| 财务费用 | -73,667,134.28 | -52,686,821.52 | -28,802,813.16 | -126,126,705.73 |
| 其中:利息费用 | 24,266,655.63 | 15,565,603.17 | 7,317,404 | 31,570,183.83 |
| 其中:利息收入 | 101,695,428.27 | 73,509,376.89 | 39,711,214.35 | 166,372,000.83 |
| 加:公允价值变动收益 | - | - | - | 10,817,458.31 |
| 加:投资收益 | 316,413,621.02 | 240,328,388.92 | 104,978,672.01 | 358,951,819.35 |
| 资产处置收益 | -136,751.71 | -54,073.85 | -2,372.8 | 83,443.4 |
| 资产减值损失(新) | -6,830,640.93 | -4,052,580.83 | -2,793,539.68 | 388,870.07 |
| 信用减值损失(新) | -46,636,044 | -43,368,268.88 | -30,175,806.35 | -9,165,197.93 |
| 其他收益 | 8,980,542.51 | 6,254,954.39 | 3,654,314.4 | 81,324,762.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,989,261,474.35 | 1,329,608,744.97 | 613,798,834.54 | 2,944,357,791.05 |
| 加:营业外收入 | 1,340,049.16 | 990,469.42 | 629,908.19 | 3,005,515.94 |
| 减:营业外支出 | 24,767,650.56 | 12,765,141.82 | 892,265.98 | 16,473,062.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,965,833,872.95 | 1,317,834,072.57 | 613,536,476.75 | 2,930,890,244.95 |
| 减:所得税费用 | 390,906,697.65 | 254,161,063.8 | 118,418,009.37 | 596,419,504.34 |
| 六、净利润 | 1,574,927,175.3 | 1,063,673,008.77 | 495,118,467.38 | 2,334,470,740.61 |
| 持续经营净利润 | 1,574,927,175.3 | 1,063,673,008.77 | 495,118,467.38 | 2,334,470,740.61 |
| 归属于母公司股东的净利润 | 1,481,271,832.85 | 1,000,510,723.1 | 459,454,518.02 | 2,145,998,746.54 |
| 少数股东损益 | 93,655,342.45 | 63,162,285.67 | 35,663,949.36 | 188,471,994.07 |
| (一)基本每股收益 | 1.96 | 1.33 | 0.61 | 2.84 |
| (二)稀释每股收益 | 1.96 | 1.33 | 0.61 | 2.84 |
| 八、其他综合收益 | -4,446,206.5 | -8,526,585.89 | -5,853,233.88 | 5,102,617.31 |
| 归属于母公司股东的其他综合收益 | -4,446,206.5 | -8,526,585.89 | -5,853,233.88 | 5,102,617.31 |
| 九、综合收益总额 | 1,570,480,968.8 | 1,055,146,422.88 | 489,265,233.5 | 2,339,573,357.92 |
| 归属于母公司股东的综合收益总额 | 1,476,825,626.35 | 991,984,137.21 | 453,601,284.14 | 2,151,101,363.85 |
| 归属于少数股东的综合收益总额 | 93,655,342.45 | 63,162,285.67 | 35,663,949.36 | 188,471,994.07 |
| 公告日期 | 2024-10-24 | 2024-08-22 | 2024-04-26 | 2024-03-21 |
| 审计意见(境内) | | | | 标准无保留意见 |